BCRX  Biocryst Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

121.74M

Vuru Grade

31.00/100

Current Price

$1.66
-0.14 (-7.78%)

Stability Price

$0.21
Overvalued by 87.09%

Company Metrics

  • P/E 0
  • P/S 2.69
  • P/B 2.06
  • EPS -0.50
  • Cash ROIC -229.93%
  • Cash Ratio 1.26
  • Dividend 0 / N/A %
  • Avg. Vol. 980,256.00
  • Shares 73.34M
  • Market Cap. 121.74M

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Needham & Company LLC Lowers BioCryst Pharmaceuticals, Inc. (BCRX) to Hold
Financial Market News - 2 hours ago
Needham & Company LLC cut shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) from a buy rating to a hold rating in a research report released on Monday morning, The Fly reports.
BioCryst Pharmaceuticals Inc. (BCRX) Drops 5.83% on February 11 - Equities.com
Piper Jaffray Lowers BioCryst Pharmaceuticals, Inc. (BCRX) to Neutral - The Vista Voice
BioCryst Pharmaceuticals Inc. (BCRX) Hits New 52-week Low During February 08 ...
Equities.com - Feb 8, 2016
BioCryst Pharmaceuticals Inc. (BCRX) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $2.40, BioCryst Pharmaceuticals Inc. dropped to $1.76 for a new 52-week low. By the closing bell, the company's ...
BioCryst Pharmaceuticals, Inc. (BCRX) Given New $18.00 Price Target at FBR & Co.
The Vista Voice - Feb 10, 2016
BioCryst Pharmaceuticals, Inc. logo BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) had its price objective boosted by FBR & Co.
BioCryst Pharmaceuticals, Inc Crashes on Failure of OPuS 2 Clinical Trial for HAE - Bidness ETC
Insider Trade: Baker Bros. Advisors Lp Bought 45000 Shares of BioCryst ... - fdanewsalert.com
Buzz Stocks: Apollo Education Group Inc, GoPro Inc, and BioCryst ...
Schaeffers Research (blog) - Feb 8, 2016
GPRO has tacked on 4.4% in electronic trading, after the company inked a patent licensing agreement with Microsoft Corporation (NASDAQ:MSFT).
The Ups and Downs of Biotech: Cerus Corporation (CERS) and BioCryst ...
Smarter Analyst - Feb 10, 2016
The volatile biotech sector did not fail to live up to its reputation this week. Analysts weigh in on Cerus Corporation (NASDAQ:CERS) as the stock spiked following a new partnership with the Red Cross.
Here's Why Shares of BioCryst Pharmaceuticals, Inc. Are Falling Today
Motley Fool - Oct 8, 2015
What: Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX), a biotech company that specializes in the development of small molecular drugs, sank by over 20% today on heavy volume.
BioCryst Pharmaceuticals (BCRX) Stock Drops Despite Positive Drug Trial Results - TheStreet.com
BioCryst Announces Successful Phase 1 Clinical Trial of BCX7353 - GlobeNewswire (press release)
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)'s Insider Baker Bros. Advisors Lp ...
fdanewsalert.com - Feb 4, 2016
Because of the purchase Baker Bros. Advisors Lp made, its in the traders attention today. The insider of Biocryst Pharmaceuticals Inc, bought 207,715 shares worth $1.34 million USD. The average cost was $6.4 per share. In the last month, Baker Bros.
20.5% Stake of BioCryst Pharmaceuticals, Inc. (BCRX) Maintained by Baker Bros ... - Financial Market News
Biocryst Pharmaceuticals (BCRX) Weak On High Volume Today
TheStreet.com - Jan 27, 2016
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases.
Franklin Street Advisors Has $712000 Stake in BioCryst Pharmaceuticals, Inc ... - IRA Market Report
BioCryst Pharmaceuticals, Inc. (BCRX) Major Shareholder Bros. Advisors Lp ... - EMQ
BioCryst Pharmaceuticals, Inc. (BCRX) Cut to "Sell" at Zacks Investment Research
EMQ - Feb 2, 2016
Zacks Investment Research lowered shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) from a hold rating to a sell rating in a report released on Wednesday morning, ARN reports.
Bros. Advisors Lp Baker Purchases 88345 Shares of BioCryst Pharmaceuticals ... - Corvus Business Newswire
Investors Tracking BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)'s - Vanguard Tribune
BioCryst Pharmaceuticals Inc. (BCRX) Hits New 52-week Low During February 05 ...
Equities.com - Feb 5, 2016
BioCryst Pharmaceuticals Inc. (BCRX) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $6.62, BioCryst Pharmaceuticals Inc. dropped to $6.18 for a new 52-week low. By the closing bell, the company's ...
Can BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Record A Positive Move? - Stocks Daily
Biocryst Pharmaceuticals Incorporated (NASDAQ:BCRX) Shorted Shares Increased 3 ... - fdanewsalert.com